Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 550

1.

Oral Squamous Cell Carcinoma as a Complication of Treatment for Recurrent High-Grade Serous Cancer.

Moses LE, Rotsides JM, Balogun FO, Persky MS, Muggia FM, Persky MJ.

Laryngoscope. 2019 Dec 4. doi: 10.1002/lary.28451. [Epub ahead of print]

PMID:
31800100
2.

Decreasing Trends of Secondary Primary Colorectal Cancer among Women with Uterine Cancer: A Population-Based Analysis.

Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Muggia FM, Roman LD, Wright JD.

J Clin Med. 2019 May 20;8(5). pii: E714. doi: 10.3390/jcm8050714.

3.

Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis.

Matsuo K, Mandelbaum RS, Machida H, Yoshihara K, Muggia FM, Roman LD, Wright JD.

Gynecol Oncol. 2019 Jul;154(1):169-176. doi: 10.1016/j.ygyno.2019.05.014. Epub 2019 May 23.

PMID:
31130286
4.

Neoadjuvant chemotherapy in patients with advanced endometrial cancer.

Khouri OR, Frey MK, Musa F, Muggia F, Lee J, Boyd L, Curtin JP, Pothuri B.

Cancer Chemother Pharmacol. 2019 Aug;84(2):281-285. doi: 10.1007/s00280-019-03838-x. Epub 2019 Apr 12.

PMID:
30980132
5.

Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.

Murthy P, Muggia F.

Ecancermedicalscience. 2019 Feb 14;13:904. doi: 10.3332/ecancer.2019.904. eCollection 2019. Review.

6.

Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study.

Blake EA, Bradley CA, Mostofizadeh S, Muggia FM, Garcia AA, Roman LD, Matsuo K.

Arch Gynecol Obstet. 2019 Jun;299(6):1641-1649. doi: 10.1007/s00404-019-05104-0. Epub 2019 Mar 1.

PMID:
30824986
7.

Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, Bender DP, Mutch DG, Friedlander ML, Van Le L, Method MW, Hamilton CA, Lee RB, Wenham RM, Guntupalli SR, Markman M, Muggia FM, Armstrong DK, Bookman MA, Burger RA, Copeland LJ.

Obstet Gynecol. 2019 Feb;133(2):245-254. doi: 10.1097/AOG.0000000000003086. Erratum in: Obstet Gynecol. 2019 Apr;133(4):830.

PMID:
30633128
8.

Platinum type is key in determining degree of neuropathy.

Muggia F, Kudlowitz D.

Gynecol Oncol Rep. 2018 Sep 5;26:32. doi: 10.1016/j.gore.2018.08.010. eCollection 2018 Nov. No abstract available.

9.

Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points.

Boyd LR, Muggia FM.

Oncology (Williston Park). 2018 Aug 15;32(8):418-20, 422-4.

10.

Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis.

Cadena I, Werth VP, Levine P, Yang A, Downey A, Curtin J, Muggia F.

Ecancermedicalscience. 2018 May 22;12:837. doi: 10.3332/ecancer.2018.837. eCollection 2018.

11.

Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.

Lee J, Curtin JP, Muggia FM, Pothuri B, Boyd LR, Blank SV.

Cancer Chemother Pharmacol. 2018 Jul;82(1):55-63. doi: 10.1007/s00280-018-3591-y. Epub 2018 Apr 27.

PMID:
29704010
12.

Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin.

Kudlowitz D, Velastegui A, Musa F, Muggia F.

Cancer Chemother Pharmacol. 2018 May;81(5):847-851. doi: 10.1007/s00280-018-3559-y. Epub 2018 Mar 7.

PMID:
29516152
13.

Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.

Kwa M, Li X, Novik Y, Oratz R, Jhaveri K, Wu J, Gu P, Meyers M, Muggia F, Speyer J, Iwano A, Bonakdar M, Kozhaya L, Tavukcuoglu E, Budan B, Raad R, Goldberg JD, Unutmaz D, Adams S.

Breast Cancer Res Treat. 2018 Feb;168(1):57-67. doi: 10.1007/s10549-017-4570-4. Epub 2017 Nov 9.

PMID:
29124456
14.

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.

Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH.

Gynecol Oncol. 2017 Nov;147(2):243-249. doi: 10.1016/j.ygyno.2017.08.004. Epub 2017 Aug 12.

15.

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.

Musa F, Pothuri B, Blank SV, Ling HT, Speyer JL, Curtin J, Boyd L, Li X, Goldberg JD, Muggia F, Tiersten A.

Gynecol Oncol. 2017 Feb;144(2):279-284. doi: 10.1016/j.ygyno.2016.11.043. Epub 2016 Dec 5.

PMID:
27931751
16.

Squamous cell carcinoma of the rectum: a consequence of immunosuppression resulting from inhibiting tumour necrosis factor (TNF)?

Silverton A, Raad RA, Katz L, Downey A, Muggia FM.

Ecancermedicalscience. 2016 Jun 7;10:646. doi: 10.3332/ecancer.2016.646. eCollection 2016.

17.

Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope.

Caron JM, Ames JJ, Contois L, Liebes L, Friesel R, Muggia F, Vary CP, Oxburgh L, Brooks PC.

Am J Pathol. 2016 Jun;186(6):1649-61. doi: 10.1016/j.ajpath.2016.01.015.

18.

Intraperitoneal Therapy for Ovarian Cancer.

Muggia FM.

J Clin Oncol. 2016 Mar 10;34(8):882. doi: 10.1200/JCO.2015.62.8370. Epub 2016 Feb 1. No abstract available.

PMID:
26834061
19.

Utility of endometrial sampling prior to risk-reducing hysterectomy in a patient with Lynch syndrome.

Frey MK, David-West G, Mittal KR, Muggia FM, Pothuri B.

Ecancermedicalscience. 2016 Jan 18;10:613. doi: 10.3332/ecancer.2016.613. eCollection 2016.

20.

[Platinum antitumor complexes].

Bonetti A, Giuliani J, Muggia F.

Recenti Prog Med. 2015 Dec;106(12):618-28. doi: 10.1701/2094.22652. Review. Italian.

PMID:
26780071
21.

Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.

Muggia FM, Bonetti A, Hoeschele JD, Rozencweig M, Howell SB.

J Clin Oncol. 2015 Dec 10;33(35):4219-26. doi: 10.1200/JCO.2015.60.7481. Epub 2015 Oct 26. No abstract available.

PMID:
26503202
22.

Clinical Trials of Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: Unanswered Questions.

Kwa M, Muggia F.

Oncology (Williston Park). 2015 Sep;29(9):702-4. No abstract available.

23.

Primary large cell neuroendocrine carcinoma of the breast, a case report with an unusual clinical course.

Janosky M, Bian J, Dhage S, Levine J, Silverman J, Jors K, Moy L, Cangiarella J, Muggia F, Adams S.

Breast J. 2015 May-Jun;21(3):303-7. doi: 10.1111/tbj.12403. Epub 2015 Mar 30.

PMID:
25823996
24.

Chronic thalidomide and chemoembolization for hepatocellular carcinoma.

Wu J, Ng J, Christos PJ, Goldenberg AS, Sparano J, Sung MW, Hochster HS, Muggia FM.

Oncologist. 2014 Dec;19(12):1229-30. doi: 10.1634/theoncologist.2014-0283. Epub 2014 Oct 31.

25.

Targeting HER2 in ovarian and uterine cancers: challenges and future directions.

Teplinsky E, Muggia F.

Gynecol Oncol. 2014 Nov;135(2):364-70. doi: 10.1016/j.ygyno.2014.09.003. Epub 2014 Sep 16. Review.

PMID:
25220628
26.

Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.

Zagar TM, Vujaskovic Z, Formenti S, Rugo H, Muggia F, O'Connor B, Myerson R, Stauffer P, Hsu IC, Diederich C, Straube W, Boss MK, Boico A, Craciunescu O, Maccarini P, Needham D, Borys N, Blackwell KL, Dewhirst MW.

Int J Hyperthermia. 2014 Aug;30(5):285-94. doi: 10.3109/02656736.2014.936049.

27.

Systemic treatment of endometrial cancer: what is doxorubicin's role?

Goldfinger M, Diaz I, Muggia F.

J Clin Oncol. 2014 Jul 10;32(20):2181-2. doi: 10.1200/JCO.2014.55.7454. Epub 2014 Jun 2. No abstract available.

PMID:
24888803
28.

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications.

Kudlowitz D, Muggia F.

Expert Opin Drug Saf. 2014 Jun;13(6):681-5. doi: 10.1517/14740338.2014.910193. Epub 2014 Apr 22. No abstract available.

PMID:
24749649
29.

Introduction: why a supplement on taxanes?

Muggia FM.

Anticancer Drugs. 2014 May;25(5):481. doi: 10.1097/CAD.0000000000000078. No abstract available.

PMID:
24705370
30.

Squamous cell carcinoma of the oral cavity in a woman with a 9-year history of ovarian cancer: is exposure to pegylated liposomal Doxorubicin a factor?

Randon G, Nicoletto MO, Milite N, Muggia F, Conte P.

Oncologist. 2014 Apr;19(4):429. doi: 10.1634/theoncologist.2013-0421. Epub 2014 Mar 25. No abstract available.

31.

Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness.

Warner E, Liebes L, Levinson B, Downey A, Tiersten A, Muggia F.

Oncologist. 2014 Mar;19(3):250. doi: 10.1634/theoncologist.2013-0398. Epub 2014 Feb 21.

32.

'BRCAness' and its implications for platinum action in gynecologic cancer.

Muggia F, Safra T.

Anticancer Res. 2014 Feb;34(2):551-6. Review.

33.

The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.

Safra T, Rogowski O, Muggia FM.

Int J Gynecol Cancer. 2014 Mar;24(3):488-95. doi: 10.1097/IGC.0000000000000086.

PMID:
24457564
34.

Platinum and other heavy metal coordinating compounds in cancer chemotherapy: overview of Verona ISPCC XI.

Muggia F, Leone R, Bonetti A.

Anticancer Res. 2014 Jan;34(1):417. No abstract available.

PMID:
24403516
35.

Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer.

Bonetti A, Giuliani J, Muggia F.

Anticancer Res. 2014 Jan;34(1):423-34. Review.

PMID:
24403498
36.

Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer.

Shavit L, Lifschitz MD, Gabizon A, Kwa M, Muggia F, Slotki I.

Kidney Int. 2014 Jan;85(1):213. doi: 10.1038/ki.2013.408. No abstract available.

37.

Novel taxanes.

Muggia F, Kudlowitz D.

Anticancer Drugs. 2014 May;25(5):593-8. doi: 10.1097/CAD.0000000000000053. Review.

PMID:
24374330
38.

Clinical features of taxane neuropathy.

Kudlowitz D, Muggia F.

Anticancer Drugs. 2014 May;25(5):495-501. doi: 10.1097/CAD.0000000000000051. Review.

PMID:
24300917
39.

Hereditary breast and ovarian cancer: lessening the burden.

Muggia F, Tommasi S, Lynch H, Paradiso A.

Ann Oncol. 2013 Nov;24 Suppl 8:viii5-viii6. No abstract available.

PMID:
24298633
40.

A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.

Stein SM, Tiersten A, Hochster HS, Blank SV, Pothuri B, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, Guddati AK, Muggia F.

Int J Gynecol Cancer. 2013 Nov;23(9):1577-82. doi: 10.1097/IGC.0b013e3182a809e0.

41.

BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.

Safra T, Lai WC, Borgato L, Nicoletto MO, Berman T, Reich E, Alvear M, Haviv I, Muggia FM.

Ann Oncol. 2013 Nov;24 Suppl 8:viii63-viii68. doi: 10.1093/annonc/mdt315.

42.

Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.

Kwa M, Edwards S, Downey A, Reich E, Wallach R, Curtin J, Muggia F.

Ann Surg Oncol. 2014 May;21(5):1468-73. doi: 10.1245/s10434-013-3277-y. Epub 2013 Oct 1.

PMID:
24081797
43.

Ovarian cancer: a brief historical overview of intraperitoneal trials.

Kwa M, Muggia F.

Ann Surg Oncol. 2014 May;21(5):1429-34. doi: 10.1245/s10434-013-3219-8. Epub 2013 Oct 1.

PMID:
24081795
44.

A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.

Kobrinsky B, Joseph SO, Muggia F, Liebes L, Beric A, Malankar A, Ivy P, Hochster H.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1073-8. doi: 10.1007/s00280-013-2295-6. Epub 2013 Sep 19.

PMID:
24048674
45.

Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature.

Teplinsky E, Cheung D, Weisberg I, Jacobs RE, Wolff M, Park J, Friedman K, Muggia F, Jhaveri K.

Breast Cancer Res Treat. 2013 Sep;141(2):167-72. doi: 10.1007/s10549-013-2681-0. Epub 2013 Sep 4. Review.

PMID:
24002736
46.

HE4: another 'player' in the epithelial tumor marker arena?

Teplinsky E, Muggia F.

Oncology (Williston Park). 2013 Jun;27(6):556, 562-3. No abstract available.

47.

Supraventricular tachycardia and urticaria complicating leuprolide-induced ovarian suppression in a young woman with breast cancer: a case report.

Sharma SP, Muggia F.

Ecancermedicalscience. 2013 Jul 24;7:335. doi: 10.3332/ecancer.2013.335. Print 2013.

48.

Defining risks of taxane neuropathy: insights from randomized clinical trials.

Kudlowitz D, Muggia F.

Clin Cancer Res. 2013 Sep 1;19(17):4570-7. doi: 10.1158/1078-0432.CCR-13-0572. Epub 2013 Jul 1. Review.

49.

Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?

Marquez-Medina D, Chachoua A, Martin-Marco A, Desai AM, Garcia-Reglero V, Salud-Salvia A, Muggia F.

Clin Transl Oncol. 2013 Nov;15(11):959-64. doi: 10.1007/s12094-013-1035-z. Epub 2013 Apr 20.

PMID:
23606352
50.

Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis.

Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, Garcia-Donas J.

Crit Rev Oncol Hematol. 2013 Oct;88(1):154-67. doi: 10.1016/j.critrevonc.2013.03.002. Epub 2013 Apr 4. Review.

PMID:
23562498

Supplemental Content

Loading ...
Support Center